Hello everyone! I am Yinghao Zhang, the Chairman of the Board of Amphiprotech. Our company focuses on the development of original drugs, dedicated to relieving the suffering of patients with various diseases. As a veteran in the pharma industry, I always feel lucky and always keep in mind our social responsibilities.

After a decade of relentless dedication,Looking back, we have many ups and downs. Thanks to all the members of Puyou. Every small step to the success is not possible with their continuous passion and hard work. The whole team is extremely down-to-earth, and we are firmly determined to develop novel drugs originated from China. By now, we have developed a number of technologies and platforms with proprietary intellectual properties. In 2023, our primary indication for dry eye disease was clinically approved by the FDA and CDE, which was a significant turning point in Puyou's development into a business with a clinical-stage product. , which is of great significance!

I sincerely hope that Amphiprotech will become a respectful company in the near future. In the pharma industry, this means that we shall earn respects from our patients and peers. To put it into practice, we shall always take our social responsibility and keep providing patients with personalized and effective molecules with excellent safety profiles. This shall stand the test of time.

It is a long journey to successfully develop a novel drug. This requires wisdom from many people. I always remind myself that we go far when we go steady with every step. At the same time, I truly hope that the society will join hands together with Amphiprotech to promote the blooming of Chinese original drugs on the wider stage!